ASE·Healthcare·$356M·#91 / 520 in Healthcare
LCTX Lineage Cell Therapeutics, Inc.
65SOLID
CATEGORY BREAKDOWN
GROWTH81
QUALITY60
STABILITY90
VALUATION6
GOVERNANCE41
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+53.2%
81
> 50% strong
Gross Margin
Revenue retained after direct costs
99.0%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
26 months
87
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
5.4%
96
< 25% strong
Price / Sales
Market cap relative to trailing revenue
24.5x
6
< 3x strong
Rule of 40
Growth rate plus operating margin
-96
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
4.9%
39
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+9.2%
45
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE LCTX WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when LCTX's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.